Abraxane: Breast And Lung Cancer Drug Almost Improves Pancreatic Cancer Survival
Patients with advanced forms of pancreatic cancer, such as those tested in the Celgene trial, typically live 5.6 to 6.8 months
abraxane breast lung cancer drug improve pancreatic cancer survival patient advanced form pancreatic cancer test celgene trial typically live month